Filter Results:
(1,253)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
- February 2010
- Supplement
Organization and Strategy at Millennium (B)
By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder CEO Mark... View Details
Keywords: Leading Change; Transformation; Decision Choices and Conditions; Crisis Management; Competitive Advantage; Commercialization; Selection and Staffing; Product Development; Organizational Change and Adaptation; Pharmaceutical Industry
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (B)." Harvard Business School Supplement 710-418, February 2010.
- June 2009 (Revised April 2017)
- Teaching Note
Merck: Managing Vioxx (A)-(G)
By: Robert Simons and Natalie Kindred
Teaching Note for [109080], [109081], [109082], [109083], [109084], [109085], and [109086]. View Details
- April 2009
- Supplement
Merck: Managing Vioxx (E)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
Keywords: Leadership; Decision Choices and Conditions; Customer Focus and Relationships; Pharmaceutical Industry
Simons, Robert L., Kathryn Rosenberg, and Natalie Kindred. "Merck: Managing Vioxx (E)." Harvard Business School Supplement 109-084, April 2009.
- 1999
- Chapter
The Economics of Drug Discovery
By: Rebecca M. Henderson and Iain Cockburn
Henderson, Rebecca M., and Iain Cockburn. "The Economics of Drug Discovery." Chap. 5 in Pharmaceutical Innovation, edited by Ralph Landau, Basil Achilladelis, and Alexander Scriabine, 308–331. Philadelphia: Chemical Heritage Press, 1999.
- August 2008 (Revised May 2009)
- Background Note
Note on Generic Drugs in the European Union
By: Robert C. Pozen and Elizabeth M. Leonard
Rules governing the introduction of generic drugs in U.S. and EU have some similarities but significant differences because of the Hatch-Waxman Act in the U.S. View Details
Keywords: Governing Rules, Regulations, and Reforms; Government Legislation; Health Care and Treatment; Trademarks; Brands and Branding; Pharmaceutical Industry; European Union; United States
Pozen, Robert C., and Elizabeth M. Leonard. "Note on Generic Drugs in the European Union." Harvard Business School Background Note 309-019, August 2008. (Revised May 2009.)
- July 2008 (Revised September 2008)
- Case
Recent Developments in the Ranbaxy Case
By: Robert C. Pozen
This brief case describes settlements Indian drug maker Ranbaxy has made with Pfizer and AstraZeneca, as well as Daiichi Kangyo's purchase of a majority shareholding in Ranbaxy in 2008. View Details
Keywords: Mergers and Acquisitions; Patents; Lawsuits and Litigation; Ownership Stake; Pharmaceutical Industry; India
Pozen, Robert C. "Recent Developments in the Ranbaxy Case." Harvard Business School Case 609-010, July 2008. (Revised September 2008.)
- September 2006
- Teaching Note
Corporate Venture Capital at Eli Lilly (TN)
By: Richard G. Hamermesh and Erin Seefeld
- September 2005 (Revised June 2006)
- Case
WuXi PharmaTech
By: Richard G. Hamermesh and Simin Zhou
WuXi Pharmatech has gone from zero to $21 million in sales in three years. The company must decide its growth strategy and how best to finance and organize for rapid growth. View Details
Keywords: Growth Management; Capital Markets; Problems and Challenges; Pharmaceutical Industry; China
Hamermesh, Richard G., and Simin Zhou. "WuXi PharmaTech." Harvard Business School Case 806-003, September 2005. (Revised June 2006.)
- March 1989 (Revised August 1989)
- Case
GI Wars: Tums vs. Rolaids—Positioning Over-the-Counter Drugs
Herzlinger, Regina E. "GI Wars: Tums vs. Rolaids—Positioning Over-the-Counter Drugs." Harvard Business School Case 189-118, March 1989. (Revised August 1989.)
- June 2004
- Case
Aventis SA (B): A Company is Born
By: Joshua D. Margolis and Carin-Isabel Knoop
Supplements the (A) case. View Details
Keywords: Problems and Challenges; Mergers and Acquisitions; Horizontal Integration; Organizational Design; Organizational Culture; Pharmaceutical Industry; United States
Margolis, Joshua D., and Carin-Isabel Knoop. "Aventis SA (B): A Company is Born." Harvard Business School Case 404-108, June 2004.
- April 2002
- Article
A Tale of Two Experts: Thalidomide and Political Engagement in the United States and West Germany
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "A Tale of Two Experts: Thalidomide and Political Engagement in the United States and West Germany." Social History of Medicine 15, no. 1 (April 2002): 137–158.
- June 2003
- Teaching Note
Discovering the Future: R&D Strategy at Merck (TN)
By: Gary P. Pisano
Teaching Note for (9-601-086). View Details
Keywords: Pharmaceutical Industry
- October 2002 (Revised June 2003)
- Background Note
New Frontiers in Target Discovery and Validation
By: Regina E. Herzlinger, Niv Caviar, Jon Chatterton and Andrea Lynn
Explains Immusol and Novartis's technology. View Details
Herzlinger, Regina E., Niv Caviar, Jon Chatterton, and Andrea Lynn. "New Frontiers in Target Discovery and Validation." Harvard Business School Background Note 303-054, October 2002. (Revised June 2003.)
- August 2001
- Case
Scios, Inc.
Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details
- March 2001 (Revised September 2002)
- Case
Merck Latin America (C): Brazil
By: Michael Beer and James Weber
Examines Merck's change effort in Brazil from the perspective of the local employees. View Details
Keywords: Change Management; Cross-Cultural and Cross-Border Issues; Multinational Firms and Management; Employees; Operations; Perspective; Pharmaceutical Industry; Brazil
Beer, Michael, and James Weber. "Merck Latin America (C): Brazil." Harvard Business School Case 401-031, March 2001. (Revised September 2002.)
- February 2000
- Case
Merck-Medco (B)
Keywords: Pharmaceutical Industry
Rangan, V. Kasturi. "Merck-Medco (B)." Harvard Business School Case 500-078, February 2000.
- February 1987 (Revised April 1987)
- Case
Eli Lilly and Co. (A)
By: William J. Bruns Jr.
Keywords: Pharmaceutical Industry
Bruns, William J., Jr. "Eli Lilly and Co. (A)." Harvard Business School Case 187-064, February 1987. (Revised April 1987.)
- March 1999 (Revised June 2000)
- Case
Eli Lilly: The Evista Project
By: Steven C. Wheelwright and Matt Verlinden
Describes the creation and operation of the initial two heavyweight teams for new drug development and launch. The primary focus is on one of the teams, Evista, although comparisons to the other team, Zyprexa, are included. Lilly must decide the next phase (postlaunch)... View Details
Keywords: Projects; Groups and Teams; Operations; Management Teams; Product Development; Transition; Product Design; Business Startups; Business Plan; Product Launch; Competition; Service Operations; Pharmaceutical Industry
Wheelwright, Steven C., and Matt Verlinden. "Eli Lilly: The Evista Project." Harvard Business School Case 699-016, March 1999. (Revised June 2000.)
- September 1993
- Supplement
Manufacturing at ALZA: The Right Prescription? (C)
ALZA, a drug delivery company, considers marketing its own and other companies' products. The primary issue is whether to build an internal sales force focused on a few niche markets, to finance a sales force through alliances, or to acquire a marketing company. View Details
Keywords: Mergers and Acquisitions; Product Marketing; Alliances; Research and Development; Salesforce Management; Business Strategy; Pharmaceutical Industry
Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (C)." Harvard Business School Supplement 694-021, September 1993.
- September 1983 (Revised November 1984)
- Case
Syntex Laboratories (B)
The recommendations of the consultants require a number of assumptions and modifications to be implemented by Syntex Labs. Presents the initial implementation plan of the company. View Details
Keywords: Organizational Change and Adaptation; Strategic Planning; Salesforce Management; Pharmaceutical Industry
Clarke, Darral G. "Syntex Laboratories (B)." Harvard Business School Case 584-034, September 1983. (Revised November 1984.)